Fact Sheet for Healthcare Providers: Nirmidas COVID-19 (SARS-CoV-2) IgM/IgG Antibody Detection Kit | NLM

Disaster Information Management Research Center | NLM

Fact Sheet for Healthcare Providers: Nirmidas COVID-19 (SARS-CoV-2) IgM/IgG Antibody Detection Kit

09/29/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 9/29/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Nirmidas COVID-19 (SARS-CoV-2) IgM/IgG Antibody Detection Kit. The Nirmidas COVID-19 (SARS-CoV-2) IgM/IgG Antibody Detection Kit is authorized for the detection of antibodies to SARS-CoV-2 in human serum and plasma (dipotassium EDTA and lithium heparin) specimens. (PDF)